Literature DB >> 25313147

Clinical characteristics of RA patients with secondary SS and association with joint damage.

Lindsay E Brown1, Michelle L Frits1, Christine K Iannaccone1, Michael E Weinblatt1, Nancy A Shadick1, Katherine P Liao2.   

Abstract

OBJECTIVES: Secondary SS (sSS) is a common extra-articular manifestation of RA. There are conflicting data regarding the association of sSS with worse joint damage. This study aims to characterize sSS patients in an RA cohort and study the association between sSS and joint damage.
METHODS: We conducted a cross-sectional study of RA patients with ≥1 year of follow-up at a large academic centre. Subjects with co-morbid diseases that can also result in sicca symptoms were excluded from the analysis. Subjects were considered to have sSS if they were reported as having sSS by their rheumatologist at recruitment into the cohort and had the diagnosis confirmed by chart review. The primary outcome was Sharp score using bilateral hand radiographs at recruitment. We constructed a linear regression model to determine the association of sSS status and Sharp score adjusted by age, gender, disease duration and ACPA and RF status.
RESULTS: We studied 829 RA subjects, mean age 57 years, 83% female, mean RA duration 13 years, 74% seropositive; 85 subjects (10.3%) had sSS. We observed a female predominance (95.3%), longer mean disease duration (16.9 years) and higher frequency of RF or ACPA positive among patients with sSS and RA. Having sSS at baseline was associated with higher Sharp scores (P = 0.03), independent of age, gender, RA disease duration and seropositive disease.
CONCLUSION: In our RA cohort, RA subjects with sSS had worse joint damage, suggesting that sSS is a marker of more aggressive disease.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Sjögren’s syndrome; hand; radiology; rheumatoid arthritis; synovium

Mesh:

Substances:

Year:  2014        PMID: 25313147      PMCID: PMC4416083          DOI: 10.1093/rheumatology/keu400

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  18 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

3.  HLA-DQB1 CAR1/CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjögren's syndrome.

Authors:  H Hadj Kacem; N Kaddour; F Z Adyel; Z Bahloul; H Ayadi
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

4.  A study of the prevalence of sicca symptoms and secondary Sjögren's syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile.

Authors:  Hans-Jacob Haga; Yusuf Naderi; Alicia Martin Moreno; Elisabeth Peen
Journal:  Int J Rheum Dis       Date:  2012-02-13       Impact factor: 2.454

Review 5.  Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages.

Authors:  S Boini; F Guillemin
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

6.  Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.

Authors:  Christine K Iannaccone; Yvonne C Lee; Jing Cui; Michelle L Frits; Roberta J Glass; Robert M Plenge; Daniel H Solomon; Michael E Weinblatt; Nancy A Shadick
Journal:  Rheumatology (Oxford)       Date:  2010-09-16       Impact factor: 7.580

7.  Characteristics of Sjögren's syndrome in rheumatoid arthritis.

Authors:  Jing He; Yan Ding; Min Feng; Jianping Guo; Xiaolin Sun; Jing Zhao; Di Yu; Zhanguo Li
Journal:  Rheumatology (Oxford)       Date:  2013-02-04       Impact factor: 7.580

8.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome.

Authors:  Filipe Barcelos; Isabel Abreu; José Vaz Patto; Hélder Trindade; Ana Teixeira
Journal:  Acta Reumatol Port       Date:  2009 Oct-Dec       Impact factor: 1.290

9.  Hand radiographic changes in patients with primary and secondary Sjögren's syndrome.

Authors:  C G Tsampoulas; F N Skopouli; D J Sartoris; P Kaplan; S Kursunoglu; C Pineda; D Resnick; H M Moutsopoulos
Journal:  Scand J Rheumatol       Date:  1986       Impact factor: 3.641

10.  Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis.

Authors:  H M Moutsopoulos; B L Webber; T P Vlagopoulos; T M Chused; J L Decker
Journal:  Am J Med       Date:  1979-05       Impact factor: 4.965

View more
  8 in total

1.  The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.

Authors:  Nancy A Shadick; Nicole M Gerlanc; Michelle L Frits; Bradley S Stolshek; Brenna L Brady; Christine Iannaccone; David Collier; Jing Cui; Alex Mutebi; Michael E Weinblatt
Journal:  Clin Rheumatol       Date:  2019-07-29       Impact factor: 2.980

2.  Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.

Authors:  Gabriel Maciel; Cynthia S Crowson; Eric L Matteson; Divi Cornec
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

3.  Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry.

Authors:  Leslie R Harrold; Ying Shan; Sabrina Rebello; Neil Kramer; Sean E Connolly; Evo Alemao; Sheila Kelly; Joel M Kremer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2020-05-24       Impact factor: 2.631

Review 4.  A paradigm shift in studies based on rheumatoid arthritis clinical registries.

Authors:  Soo-Kyung Cho; Yoon-Kyoung Sung
Journal:  Korean J Intern Med       Date:  2019-02-18       Impact factor: 2.884

5.  Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.

Authors:  Huijuan Zhang; Haoze Zhang; Dai Gao; Wenhui Xie; Yan Geng; Zhuoli Zhang
Journal:  Arthritis Res Ther       Date:  2020-05-01       Impact factor: 5.156

6.  Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study.

Authors:  Daisuke Waki; Hiroya Tamai; Ritsuko Yokochi; Toshiki Kido; Yuriko Yagyu; Ryo Yanai; Ken-Ei Sada
Journal:  PLoS One       Date:  2022-07-22       Impact factor: 3.752

7.  Sjögren's syndrome.

Authors:  Fiona André; Barbara C Böckle
Journal:  J Dtsch Dermatol Ges       Date:  2022-07-01       Impact factor: 5.231

8.  Deep learning-based automatic-bone-destruction-evaluation system using contextual information from other joints.

Authors:  Kazuki Miyama; Ryoma Bise; Satoshi Ikemura; Kazuhiro Kai; Masaya Kanahori; Shinkichi Arisumi; Taisuke Uchida; Yasuharu Nakashima; Seiichi Uchida
Journal:  Arthritis Res Ther       Date:  2022-10-03       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.